Eli Lilly moved to expand its gene‑therapy footprint by acquiring Adverum’s assets, reinforcing the company’s commitment to AAV‑based retinal and ocular programs. The deal positions Lilly to deepen its presence in gene therapy during a period when some large pharmas are reassessing investments in the modality. Company statements describe the transaction as a targeted, strategic step to bolster Lilly’s regenerative and genetic medicine capabilities while integrating Adverum’s platform and expertise.